Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer.
PARP inhibitor
biomarkers
homologous recombination deficiency
ovarian cancer
replication stress
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2023
2023
Historique:
received:
06
09
2022
accepted:
30
01
2023
entrez:
6
3
2023
pubmed:
7
3
2023
medline:
7
3
2023
Statut:
epublish
Résumé
Poly (ADP-ribose) polymerase inhibitors (PARPis) represent a therapeutic milestone in the management of epithelial ovarian cancer. The concept of 'synthetic lethality' is exploited by PARPi in tumors with defects in DNA repair pathways, particularly homologous recombination deficiency. The use of PARPis has been increasing since its approval as maintenance therapy, particularly in the first-line setting. Therefore, resistance to PARPi is an emerging issue in clinical practice. It brings an urgent need to elucidate and identify the mechanisms of PARPi resistance. Ongoing studies address this challenge and investigate potential therapeutic strategies to prevent, overcome, or re-sensitize tumor cells to PARPi. This review aims to summarize the mechanisms of resistance to PARPi, discuss emerging strategies to treat patients post-PARPi progression, and discuss potential biomarkers of resistance.
Identifiants
pubmed: 36872947
doi: 10.1177/17588359231157644
pii: 10.1177_17588359231157644
pmc: PMC9983116
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
17588359231157644Informations de copyright
© The Author(s), 2023.
Déclaration de conflit d'intérêts
Ana C. Veneziani and Matthew J. Wakefield declare no conflicts of interest. Stephanie Lheureux received honoraria from GSK, AstraZeneca, Merck, Eisai, Roche, and Novartis. She received grant support from GSK, Astra-Zeneca, and Roche. She is the principal investigator and co-investigator of different industry and investigational studies involved with PARP inhibitors (Astra-Zeneca, Clovis, GSK, Repare Therapeutics). Clare Scott reports non-financial support from Clovis Oncology, grants and other support from Eisai Inc, AstraZeneca, Sierra Oncology, MSD, grants from Boehringer Ingelheim, other support from Roche, Takeda, and non-financial support from Beigene. She is the principal investigator and co-investigator of clinical trials involving PARP inhibitors (Clovis Oncology and AstraZeneca). Anna Tinker received honoraria from GSK, AstraZeneca, Merck, and Eisai. She received grant support from Astra-Zeneca.
Références
Cancer Drug Resist. 2022 May 12;5(2):424-435
pubmed: 35800366
Nat Cell Biol. 2017 Nov;19(11):1371-1378
pubmed: 29035360
Nat Commun. 2020 Nov 30;11(1):6118
pubmed: 33257658
Nature. 2015 May 28;521(7553):541-544
pubmed: 25799992
J Pharm Sci. 2014 Jun;103(6):1913-20
pubmed: 24700236
J Med Chem. 2003 Nov 6;46(23):4805-17
pubmed: 14584929
Anticancer Res. 2022 Apr;42(4):2017-2022
pubmed: 35347023
Nature. 2012 Jan 18;481(7381):287-94
pubmed: 22258607
Mol Pharmacol. 2005 Dec;68(6):1636-44
pubmed: 16126823
Gynecol Oncol. 2018 Jun;149(3):575-584
pubmed: 29567272
Oncogene. 2020 Jun;39(25):4869-4883
pubmed: 32444694
Br J Cancer. 2016 Aug 9;115(4):431-41
pubmed: 27415012
Nature. 2016 Jul 20;535(7612):382-7
pubmed: 27443740
J Hematol Oncol. 2019 Apr 24;12(1):43
pubmed: 31018854
Nat Commun. 2020 Nov 4;11(1):5584
pubmed: 33149131
J Hematol Oncol. 2020 Sep 21;13(1):126
pubmed: 32958072
Gynecol Oncol. 2020 Dec;159(3):887-898
pubmed: 33012552
Nucleic Acids Res. 2007;35(16):5312-22
pubmed: 17690115
Clin Cancer Res. 2017 Jul 15;23(14):3711-3720
pubmed: 28167507
Clin Cancer Res. 2017 Nov 1;23(21):6708-6720
pubmed: 28765325
Lancet. 2017 Oct 28;390(10106):1949-1961
pubmed: 28916367
Am Soc Clin Oncol Educ Book. 2019 Jan;39:185-195
pubmed: 31099635
Mol Cancer Res. 2018 Feb;16(2):222-232
pubmed: 29133592
J Clin Oncol. 2023 Jan 30;:JCO2201900
pubmed: 36716407
Cancer Discov. 2020 Oct;10(10):1528-1543
pubmed: 32532747
Cancer Res. 2010 Jun 15;70(12):4880-90
pubmed: 20516115
Mol Cell Biol. 2004 Dec;24(23):10381-9
pubmed: 15542845
Ann Oncol. 2022 Oct;33(10):1021-1028
pubmed: 35772665
Cancer Cell. 2019 Mar 18;35(3):519-533.e8
pubmed: 30889383
Nat Rev Clin Oncol. 2021 Dec;18(12):773-791
pubmed: 34285417
Nature. 2015 May 28;521(7553):489-94
pubmed: 26017449
Nat Commun. 2021 May 3;12(1):2487
pubmed: 33941784
Nat Commun. 2022 Jun 28;13(1):3707
pubmed: 35764636
Cancer J. 2021 Nov-Dec 01;27(6):521-528
pubmed: 34904816
Nature. 2005 Apr 14;434(7035):917-21
pubmed: 15829967
Cancers (Basel). 2020 Jul 25;12(8):
pubmed: 32722408
Cancer Treat Rev. 2018 Dec;71:1-7
pubmed: 30269007
Gynecol Oncol Rep. 2022 Feb 02;40:100939
pubmed: 35169607
Cancer Cell. 2018 Mar 12;33(3):401-416.e8
pubmed: 29533782
Genes Dev. 2014 Dec 15;28(24):2693-8
pubmed: 25512557
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Science. 2020 Apr 3;368(6486):
pubmed: 32241924
J Clin Oncol. 2022 Dec 1;40(34):3952-3964
pubmed: 35658487
Cancers (Basel). 2020 Jun 17;12(6):
pubmed: 32560564
Nat Commun. 2021 Sep 22;12(1):5574
pubmed: 34552099
CA Cancer J Clin. 2018 Jul;68(4):284-296
pubmed: 29809280
J Natl Cancer Inst. 2016 Oct 5;109(1):
pubmed: 27707838
J Clin Oncol. 2017 Apr 10;35(11):1240-1249
pubmed: 28221868
Sci Transl Med. 2017 May 31;9(392):
pubmed: 28566428
Nat Commun. 2020 Apr 14;11(1):1833
pubmed: 32286255
J Clin Oncol. 2017 Apr 20;35(12):1274-1280
pubmed: 28414925
Lancet Oncol. 2020 Jul;21(7):957-968
pubmed: 32553118
Cell. 2016 Jul 28;166(3):755-765
pubmed: 27372738
Genes Dev. 2017 Feb 1;31(3):318-332
pubmed: 28242626
Clin Cancer Res. 2020 Aug 15;26(16):4268-4279
pubmed: 32398324
Cancer Discov. 2019 Feb;9(2):210-219
pubmed: 30425037
Nature. 2018 Nov;563(7732):522-526
pubmed: 30464262
Mol Cancer Res. 2020 Jan;18(1):3-19
pubmed: 31659006
J Pathol. 2018 Apr;244(5):586-597
pubmed: 29282716
Cancer Res. 2022 Apr 15;82(8):1646-1657
pubmed: 35425960
Mol Cancer Ther. 2021 Mar;20(3):541-552
pubmed: 33653945
J Ovarian Res. 2018 Jun 20;11(1):50
pubmed: 29925418
Nature. 2022 Apr;604(7907):749-756
pubmed: 35444283
Cancer Lett. 2020 Jan 1;468:59-71
pubmed: 31610267
Genes Dev. 2005 Sep 1;19(17):1951-67
pubmed: 16140981
Cell Rep. 2018 Apr 03;23(1):239-254.e6
pubmed: 29617664
Nat Cancer. 2021 Jun;2(6):598-610
pubmed: 34179826
Br J Cancer. 2022 Jan;126(1):120-128
pubmed: 34732853
Mol Cell. 2017 Aug 3;67(3):374-386.e5
pubmed: 28735897
Nat Rev Genet. 2019 Nov;20(11):657-674
pubmed: 31358977
Proc Natl Acad Sci U S A. 2013 Nov 26;110(48):19489-94
pubmed: 24218601
Curr Cancer Drug Targets. 2013 Oct;13(8):814-28
pubmed: 23876050
Cancer Treat Rev. 2019 Nov;80:101909
pubmed: 31629204
J Pathol. 2013 Feb;229(3):422-9
pubmed: 23165508
Cancers (Basel). 2020 Mar 17;12(3):
pubmed: 32192091
Lancet Oncol. 2022 Apr;23(4):465-478
pubmed: 35298906
Annu Rev Cancer Biol. 2018 Mar;2:313-336
pubmed: 30345412
Nat Commun. 2019 Mar 20;10(1):1295
pubmed: 30894541
Cancer Discov. 2017 Sep;7(9):984-998
pubmed: 28588062
Sci Transl Med. 2017 Jul 26;9(400):
pubmed: 28747513
Gynecol Oncol. 2015 Mar;136(3):554-61
pubmed: 25560806
Nat Rev Drug Discov. 2023 Jan;22(1):38-58
pubmed: 36202931
Nat Commun. 2018 Sep 28;9(1):3970
pubmed: 30266954
Cancer Cell. 2018 Jun 11;33(6):1078-1093.e12
pubmed: 29894693
Cancer Cell. 2019 Jun 10;35(6):851-867.e7
pubmed: 31185210
Nat Commun. 2019 Jul 17;10(1):3143
pubmed: 31316060
Nature. 2020 Mar;579(7800):598-602
pubmed: 32028527
JAMA Oncol. 2019 Aug 01;5(8):1141-1149
pubmed: 31194228
Clin Cancer Res. 2020 Aug 15;26(16):4206-4215
pubmed: 32444417
Lancet Oncol. 2017 Jan;18(1):75-87
pubmed: 27908594
Front Cell Dev Biol. 2021 May 20;9:637675
pubmed: 34095111
Lancet Oncol. 2020 Sep;21(9):1155-1164
pubmed: 32771088
Nature. 2008 Feb 28;451(7182):1111-5
pubmed: 18264088
Mol Cancer Ther. 2021 Nov;20(11):2117-2128
pubmed: 34518297
Cancer Res. 2021 Sep 15;81(18):4709-4722
pubmed: 34321239
Nat Med. 2016 Feb;22(2):194-201
pubmed: 26779812
Nat Cell Biol. 2018 Aug;20(8):954-965
pubmed: 30022119
Cancers (Basel). 2019 Mar 23;11(3):
pubmed: 30909618
Nat Commun. 2018 May 10;9(1):1849
pubmed: 29748565
Cell. 2011 May 13;145(4):529-42
pubmed: 21565612
Cancer Discov. 2019 Jun;9(6):722-737
pubmed: 31015319
Nat Commun. 2013;4:2993
pubmed: 24356582
Mol Cell. 2018 Feb 1;69(3):371-384.e6
pubmed: 29395061
Trends Cell Biol. 2019 Oct;29(10):820-834
pubmed: 31421928
Nat Commun. 2021 Jun 17;12(1):3636
pubmed: 34140467
Drug Resist Updat. 2015 Jan;18:1-17
pubmed: 25554624
Gynecol Oncol. 2020 Dec;159(3):877-886
pubmed: 32967790
Cancer Discov. 2017 Sep;7(9):999-1005
pubmed: 28450426
J Natl Cancer Inst. 2016 Jul 05;108(11):
pubmed: 27381626
Gynecol Oncol. 2021 Nov;163(2):246-253
pubmed: 34620496
Nature. 2018 Aug;560(7716):117-121
pubmed: 30022168
Ann Oncol. 2013 Oct;24 Suppl 6:vi24-32
pubmed: 24078660
Science. 2013 Feb 8;339(6120):700-4
pubmed: 23306437
Cancers (Basel). 2022 Feb 14;14(4):
pubmed: 35205700
Nat Struct Mol Biol. 2010 Jun;17(6):688-95
pubmed: 20453858
J Clin Oncol. 2023 Jan 20;41(3):609-617
pubmed: 36082969
Mol Cell. 2016 Aug 18;63(4):662-673
pubmed: 27453047
Oncogene. 2022 Jun;41(26):3498-3506
pubmed: 35662281
FEBS J. 2022 Dec;289(24):7854-7868
pubmed: 34601817
Cancers (Basel). 2022 May 26;14(11):
pubmed: 35681617
Cancer Res. 2019 Jan 15;79(2):311-319
pubmed: 30482774
J Biol Chem. 2005 Oct 21;280(42):35767-75
pubmed: 16115861
Mol Cell. 2020 Jan 2;77(1):26-38.e7
pubmed: 31653568
EBioMedicine. 2019 May;43:225-237
pubmed: 30898650
Cell Biosci. 2017 Jan 13;7:6
pubmed: 28101326
N Engl J Med. 2019 Dec 19;381(25):2391-2402
pubmed: 31562799
Lancet Oncol. 2021 Dec;22(12):1721-1731
pubmed: 34715071
Clin Cancer Res. 2022 Oct 3;28(19):4186-4193
pubmed: 35917514
Genes Dev. 2020 Jan 1;34(1-2):7-23
pubmed: 31896689
Mol Cell. 2017 Oct 19;68(2):414-430.e8
pubmed: 29053959
Clin Cancer Res. 2021 Oct 15;27(20):5681-5687
pubmed: 34380641
Cell. 2010 Apr 16;141(2):243-54
pubmed: 20362325
Nat Med. 2017 Apr;23(4):517-525
pubmed: 28288110